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Interferons (IFNs) direct innate and acquired immune
responses and, accordingly, are used therapeutically
to treat a number of diseases, yet the diverse effects
they elicit are not fully understood. Here, we identi-
fied the promyelocytic leukemia zinc finger (PLZF)
protein as a previously unrecognized component of
the IFN response. IFN stimulated an association of
PLZF with promyelocytic leukemia protein (PML)
and histone deacetylase 1 (HDAC1) to induce a deci-
sive subset of IFN-stimulated genes (ISGs). Conse-
quently, PLZF-deficient mice had a specific ISG
expression defect and as a result were more suscep-
tible to viral infection. This susceptibility correlated
with a marked decrease in the expression of the
key antiviral mediators and an impaired IFN-medi-
ated induction of natural killer cell function. These
results provide new insights into the regulatory
mechanisms of IFN signaling and the induction of
innate antiviral immunity.
INTRODUCTION
Type I interferons (IFNs) regulate diverse cellular functions by
modulating the expression of a large family of IFN-stimulated
genes (ISGs) through the activation of the Janus kinase (JAK)
and signal transducers and activators of transcription (STAT)
proteins (Haque and Williams, 1998; Stark et al., 1998). ISGs
subsequently influence multiple pathways involved in cell stress
responses, apoptosis, and proliferation and mediate diverse
immune effects (Goh et al., 1999; Goodbourn et al., 2000). The
potent immune response elicited by IFNs is exemplified by the
establishment of an antiviral state that enabled their original802 Immunity 30, 802–816, June 19, 2009 ª2009 Elsevier Inc.discovery (Isaacs et al., 1957). This state relies on the induction
and activation of numerous intrinsic antiviral factors, most
notably the Mx GTPases, the 20-50-oligoadenylate-synthetase
(OAS) system, ISG15, andprotein kinaseR (PKR) (Sadler andWil-
liams, 2008). In addition, IFNs modulate distinct aspects of both
innate and adaptive immunity, affecting the activities of macro-
phages, natural killer (NK) cells, dendritic cells, and T cells by
enhancing ISG expression profiles, cell differentiation, cell traf-
ficking, and antigen presentation. Because of the numerous
effects of IFNs, they have been used therapeutically against
a variety of diseases, including viral infections, immunomodula-
tory disorders, and hematological and solid tumors (Borden
et al., 2007). The factors determining the outcome of IFN treat-
ment, however, are not understood, and IFN therapy has had
variable success. Although the essential JAK-STAT signal trans-
duction pathway is well characterized, recent studies have re-
vealed greater complexity in patterns of gene induction than
initially envisaged (Chang et al., 2004; Tenoever et al., 2007;
van Boxel-Dezaire et al., 2006). Here, we identified an IFN-medi-
ated signal that leads to activation of the promyelocytic leukemia
zinc finger protein (PLZF, encoded by Zbtb16) transcription
factor that has fundamental consequences for the immune
response.
PLZF is a member of the ‘‘BTB-POZ’’ (bric a´ brac, tramtrack,
broad complex-poxvirus zinc finger) family of transcription
factors and represses genes by recruiting several different core-
pressor complexes. Two recent reports describe a role for PLZF
in the immune response as a transcription factor that is neces-
sary for full function of natural killer T (NKT) cells (Kovalovsky
et al., 2008; Savage et al., 2008), although the mechanisms
were not investigated. Here, we present evidence that the role
of PLZF in the immune response is broader than described in
these reports. Contrary to the previous designation of PLZF as
a repressor of transcription, we showed that PLZF was required
for the induction of a subset of ISGs that are crucial in the
ensuing immune response via the induction of the antiviral genes
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ings provide new insights into the regulation of IFN-mediated
immunity.
RESULTS
PLZF Regulates Sensitivity to IFN
To determine the factors contributing to IFN sensitivity, we
analyzed two renal cancer cell lines, differing markedly in their
response to IFN (Holko andWilliams, 2006), for their ISG profiles.
Higher and more persistent expression of a subset of ISGs was
noted in the IFN-sensitive RCC1 cells when compared with the
relatively IFN-insensitive ACHN cells (Figure 1A). Correspond-
ingly, RCC1 cells showed an increased IFN-mediated antiviral
response (Figure S1 available online). No differences in estab-
lished IFN-regulatory factors were apparent between the two
cell lines (Holko and Williams, 2006). Therefore, to account for
the differential regulation of this subset of ISGs, we analyzed
the promoter proximal regions (1000 bp upstream of the ATG)
for features that distinguished these genes from other ISGs that
were synchronous between the two cell lines. It was found that
genes differentially induced by IFNa treatment in the RCC1 cells
exhibited an overrepresentation of DNA-binding motifs for the
PLZF protein (Table S1). Cluster analysis showed the putative
PLZF-binding sites were in proximity to sites occupied by essen-
tial STAT and IFN regulatory factors (IRFs), increasing the likeli-
hood that these motifs were biologically relevant (Figure S2). To
test this correlation between expression of ISGs with putative
binding motifs and expression of the transcription factor, we as-
sessed both cell lines for their expression of PLZF by immunoblot
analysis. Consistent with a role for PLZF in the IFN response, the
IFN-sensitive RCC1 cells expressed higher amounts of PLZF
than the relatively IFN-insensitive ACHN cells (Figure 1B).
We further investigated this correlation between IFN sensitivity
and expression of PLZF by using a monocytic U937 cell line
stably transformed with a tetracycline-inducible PLZF-express-
ing construct (U937T:PLZF45) (McConnell et al., 2003). The
ISG expression profiles of U937T:PLZF45 cells with and without
tetracycline and IFNawere examined. PLZF expression alone re-
sulted in the induction of a subset of ISGs and this was further
enhanced by IFNa (Figure 1C and Table S2). The expression of
representative ISGs was validated with real time RT-PCR
(Figure 1D). Interestingly, an analysis of gene categories regu-
lated by PLZF identified overrepresentation of immune response
genes, particularly ISGs (Tables S3–S5), suggesting a particular
role for PLZF in mediating the immune response.
PLZF Is Required for the IFN-Mediated
Antiviral Response
To evaluate the contribution of PLZF to immune function, the
IFN-mediated antiviral response was measured in embryonic
fibroblasts (MEFs) derived from PLZF-deficient (Zbtb16/)
mice. Wild-type MEFs showed 100-fold greater IFN-mediated
protection to infection with Semliki Forest Virus (SFV) than
Zbtb16/ MEFs (Figure 2A and Figure S3). The role of PLZF in
the in vivo IFN-mediated antiviral response was assessed by
infectious challenge of Zbtb16/ and wild-type neonatal mice.
Mice were infected with SFV at ten times the half-maximal tissue
culture infectious dose (TCID50), and resistance to the virus wasmeasured as survival after infection. The survival curve of in-
fected Zbtb16/ mice closely parallels the wild-type, with all
mice of both genotypes dead by 3.5 days after infection
(Figure 2B) (p > 0.05). Appropriately, IFN pretreatment of mice
for 6 hr before exposure to SFV afforded significant protection
to wild-type mice, with 60% of infected neonates (18 of 30)
surviving past 22 days. In contrast, IFN pretreatment did not
protect the Zbtb16/ mice from SFV infection, with no survival
beyond 6 days after infection (Figure 2B). Viral loads in the
organs from Zbtb16/ and wild-type neonatal mice were
measured 48 hr after infection with SFV. Consistent with the
survival results, viral titers in the organs of Zbtb16/ mice,
including the lung, thymus, spleen, heart and liver, were up to
1,000-fold greater than their wild-type littermates (Figure 2C).
The observed immune impairment in Zbtb16/ mice was not
restricted to an increased susceptibility to infection by SFV.
Wild-typeandZbtb16/micehaddramatically different suscep-
tibility to infection with the encephalomyocarditis virus (EMCV).
Intraperitoneal injection, with 500 plaque-forming units of
EMCV, of 8- to 10-week-old mice showed that wild-type mice
had significantly better survival over their Zbtb16/ littermates
(Figure 2D). These results show that PLZF is a key component
of the innate immune response and is essential for resistance to
virus infection in vivo.
PLZF Regulates Antiviral Effectors
In order to characterize the mechanism by which PLZF elicits an
antiviral state, we analyzed IFN production and ISG expression in
wild-type and Zbtb16/ mice. Notably, the serum IFN concen-
trations were not obviously deficient in infected Zbtb16/ mice
(Figure 3A). This indicated that the observed virus susceptibility
is independent of IFN production. The expression profile of
a number of PLZF-dependent ISGs, identified in array experi-
ments (Figures 1A and 1C and Table S2), was investigated
ex vivo and in vivo. Importantly, the induction of the antiviral
gene Oas1g by IFN was impaired in primary Zbtb16/ bone-
marrow-derived macrophages (BMMs) (Figure 3B). Given that
OAS1 is an established effector for the antiviral action of IFN,
specifically against SFV (Borden et al., 2007; Pestka et al.,
1987), we measured its expression in different organs after IFN
treatment and SFV infection. The induction of Oas1g was mark-
edly impaired in splenocytes isolated from the Zbtb16/ mice
(Figures 3C–3E). Similarly, the antiviral ISGs Rsad2 (also termed
Cig5 or Viperin) and Ifit2 (or Ifi54) were impaired in Zbtb16/
BMMs (Figure 3B) and splenocytes (data not shown), or SFV-in-
fected organs from Zbtb16/ mice (Figures 3C–3E). In keeping
with the specificity of the PLZF response, expression of the
PLZF-independent but IFN-regulated CCL5 (RANTES) transcript
was not affected (Figure 3B). These data suggest that the
increased susceptibility of Zbtb16/ mice is due to a specific
defect in the induction of antiviral genes.
A direct comparison of PLZF-independent and -dependent
genes was made by comparison of the closely related Ifit1 and
Ifit2 genes. Both IFIT1 and IFIT2 are strongly induced by IFN or
viral infecton and are impaired in STAT1-deficient mice. These
two genes are reported to have contrasting expression patterns
in different tissues (Terenzi et al., 2007). Both genes contain ISRE
binding sites in their promoter, but there is no PLZF-bindingmotif
in the Ifit1 promoter. Accordingly, Ifit2 induction was lost in the
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Figure 2. PLZF Is Required for the IFN-Mediated Antiviral Response
(A) Antiviral assay on wild-type (WT) and PLZF-deficient (Zbtb16/) MEFs infected with SFV for 48 and 72 hr. IFNa1 was added to cells at the indicated concen-
trations 16 hr prior to infection. The titers of IFNa required to protect cells from the cytopathic effects of SFV infection are expressed as percentage survival. Error
bars represent 1 standard deviation (SD).
(B) Survival after SFV infection of neonatal mice. WT or Zbtb16/ neonatal mice between 5 and 6 days of age were divided into two groups: either a control group
for each genotype (without IFN pretreatment: WT, n = 11; Zbtb16/, n = 8) or an IFN pretreatment group (WT, n = 30; Zbtb16/, n = 12). The IFN pretreatment
groupwas given 5000 IU IFNa; the control groupwas injectedwith PBS. After 6 hr, all micewere infectedwith SFV at 303 TCID50 andweremonitored.Without IFN
treatment, there was no significant difference in resistance to infection with SFV at 303 TCID50 in WT and Zbtb16
/ neonatal mice (p > 0.05, log-rank test). With
IFN pretreatment, wild-type mice showed more resistance in response to SFV than Zbtb16/ mice (***p < 0.001, log-rank test).
(C) Increased virus replication inZbtb16/mice.Neonatalmice fromZbtb16+/matingswere injectedwith IFNa1 andSFVbetween 5and6days of age. Neonates
were monitored for 72 hr, at which time they were killed and organs were collected. Viral titers were measured by CPE assay and expressed as mean log titer ±
SEM. *p < 0.05; **p < 0.01; and ***p < 0.001; Zbtb16/ neonatal mice (n = 7) versus their wild-type littermates (n = 8; Mann-Whitney rank sum tests).
(D)Zbtb16/micealso show increased susceptibility to lethal infectionswithEMCV.Zbtb16/mice (n=5) andWT littermatecontrols (n=7)were injected i.p.with
500 pfu of EMCV andmonitored for survival. Zbtb16/mice died after a mean survival time of 4 days, whereasWTmice survived for amean of 7 days (p = 0.009).absence of PLZF, whereas Ifit1 was still induced by IFNa in
Zbtb16/mice (Figure 3F). Furthermore, analysis of the expres-
sion of PLZF in different tissues showed a strong correlation
between PLZF expression and Ifit2 induction in response to
IFNa (Figure 3F). Hence, the different expression patterns ofthese two related ISGs probably depend upon their separate
regulation by PLZF. Although expression of IFIT1 is largely inde-
pendent of PLZF, a degree of PLZF dependence is noted in the
lung of mice, suggesting that PLZF might still contribute indi-
rectly to inducer-specific ISG regulation.Figure 1. PLZF Regulates Sensitivity to IFN
To determine factors contributing to IFN sensitivity, two RCC cell lines, ACHN and RCC1, were analyzed for ISG expression and response to IFN treatment.
(A) ISGs induced by 1000 IU/ml IFNa-2b at any one time point in either ACHN or RCC1 cells. Red indicates induced genes, yellow indicates no change, and green
indicates repressed genes (top-left panel). The bar graph below shows the number of genes induced at least 1.5-fold for each sample. A total of 22 ISGs with
higher and more persistent expression in the IFN-sensitive RCC1 cells is shown (top-right panel).
(B) Immunoblot analysis of PLZF expression in ACHN and RCC1 cells in the presence or absence of IFNa. Data are representative of three independent exper-
iments.
(C) ISGs expressed in PLZF-inducible U937T cells, treated with IFNa for 6, 16, and 24 hr in the presence and absence of PLZF expression (24 hr after tetracycline
withdrawal). The bar graph below shows the number of genes induced at least 2-fold for each sample.
(D) Expression of select genes (Table S4) was verified with SYBR Green real-time RT-PCR. Data are shown as mRNA expression normalized to the GAPDH RNA.
Data were confirmed in three independent experiments.Immunity 30, 802–816, June 19, 2009 ª2009 Elsevier Inc. 805
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Figure 3. PLZF Regulates Antiviral Effectors
(A) Serum IFN concentrations from neonatal wild-type (WT) and Zbtb16/mice injected with IFNa, with and without SFV injection. IFN was measured after 48 hr
by CPE reduction assay. Bar graphs show mean ± SD of five mice for each group.
(B) IFN-induced ISG expression of the antiviral IFN effectors OAS1, RSAD2, and IFIT2, and the chemokines CXCL10 (IP-10) and CCL5 (RANTES) were measured
in WT or Zbtb16/ BMMs after IFNa treatment for 6 hr. Data are shown as mRNA expression normalized to the 18S RNA. Bar graphs show mean ± SD of three
independent experiments.
(C–E) ThemRNA expression of the chemokine CXCL10 (IP-10) and the antiviral ISGsOAS1, RSAD2, and IFIT2wasmeasured in predominantly NK cell-rich organs
(spleen, liver, and lung) from WT and Zbtb16/ neonatal mice after IFNa treatment and SFV infection. RNA samples were analyzed for ISG expression with
a custom ISG probe.
Data are representative of three independent experiments (mean ± SEM; A–E).806 Immunity 30, 802–816, June 19, 2009 ª2009 Elsevier Inc.
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organs after IFN treatment only, or IFN treatment and SFV infec-
tion, revealed that the induction of CXCL10 by IFNa was
impaired in primary Zbtb16/ BMMs (Figure 3B). CXCL10 was
also markedly impaired in splenocytes, liver, and lung isolated
from the SFV-infected Zbtb16/ mice (Figures 3C–3E).
CXCL10 (or IP-10) has been associated with NK cell activity
and the resulting protection from virus infection (Biron et al.,
1999; Thapa et al., 2008). Therefore, an additional means by
which PLZF might regulate sensitivity to virus, besides inducing
direct antiviral effectors, could be a result of IFN-mediated acti-
vation of NK cells via ISGs such as CXCL10. This possibility was
investigated.
NK Cell Activation Is Impaired in Zbtb16/ Mice
Two recent reports have shown that PLZF affects NKT cell
activity (Kovalovsky et al., 2008; Savage et al., 2008). However,
analysis of PLZF expression in immune cells with the human
and mouse microarray database (Gene Expression Omnibus
[GEO] accession number GSE 6887) revealed that PLZF was
also expressed in human NK cells (Figure S4). Furthermore, we
demonstrated that PLZF was expressed in mouse NK cells by
sorting different spleen lymphocyte populations with FACS
(NK1.1+CD3) and then analyzing their gene expression
(Figure 4A). This analysis shows comparatively little expression
in CD3+NK1.1 T cells and no detectable transcript in B cells.
Consequently, we investigated the effect of the loss of PLZF on
NK cell function. FACS analysis of splenocytes showed there
were equivalent numbers of NK cells in wild-type and Zbtb16/
mice, with NK cells constituting 2%–3% of total splenocytes
(Figure 4B). We investigated the effector function of NK cells
from wild-type and Zbtb16/ mice by testing their cytolytic
activity against the NK-sensitive target cell line YAC-1 (Fehniger
et al., 2007; Shey andBallas, 2008). After treatmentwith poly(I:C),
which activates NK cells through the IFNa signaling pathway,
Zbtb16/NKcellswere impaired in their ability to spontaneously
lyseYAC-1cells (Figure 4C, toppanel).Moreover,whenactivated
in vivowith IFNa, the ability ofZbtb16/NKcells to subsequently
lyse YAC-1 target cells was also markedly impaired (Figure 4C,
bottom panel). These results demonstrate that PLZF is required
for NK cell effector function and also suggest that PLZF may
regulate the expression of target genes involved in NK cytolytic
activity.Given that cytokine-inducedactivationofNKcells results
in a dramatic increase in the expression of Granzyme B (GzmB),
we examined the ability of poly(I:C) and IL-2 to induce GzmB
protein expression inmurine splenic NK cells. Micewere injected
intraperitoneally with poly(I:C) or PBS, and splenic NK cells were
analyzed after 24 hr for GzmB expression by flow cytometry.
Wild-type spleens of poly(I:C)-injected mice had a markedly
higher percentage of NK cells positive for GzmB than spleens
of Zbtb16/ mice (Figure 4D). The reduced amount of GzmB is
consistent with a reduced ability to lyse target cells. Activation
of NK cells in vitro with IL-2 induced equivalent amounts of
GzmB in either genotype (data not shown). Therefore, the roleof PLZF in the induction of GzmB is through IFNa, rather than
other cytokines.
PLZF Directly Regulates the Promoters
of a Subset of ISGs
Next we sought to define the mechanism by which PLZF
enhanced the expression of a specific subset of ISGs. Treatment
of U937T:PLZF45 cells with the transcriptional inhibitor actino-
mycin D suggested that the induction of selected ISGs by
PLZF is a primary transcriptional event (Figure S5). Promoter
regions from the PLZF-regulated transcripts Rsad2 and Ifit2
were fused to luciferase and activity was measured after IFN
treatment. Overexpression of PLZF in RCC1 or ACHN cells pro-
duced a dose-dependent induction of the reporter promoters.
This effect was further enhanced by IFNa treatment (Figures
5A–5C). Correspondingly, induction of the Rsad2 promoter
was impaired in cells with PLZF expression reduced by RNA
interference (Figure 5D). Reporter constructs confirm the
requirement to colocate ISRE and PLZF-binding sites in the
promoters of PLZF-regulated ISGs (Figure S6). A direct associa-
tion of PLZF with the promoters of Rsad2 and Ifit2 was demon-
strated by chromatin immunoprecipitation assays in the RCC1
and U937T:PLZF45 cell lines. Moreover, the association of
PLZF to the Rsad2 and Ifit2 promoters was dramatically
enhanced by IFN treatment (Figure 5E and Figure S7).
IFN Activates PLZF
The observed IFN-enhanced association of PLZF with select ISG
promoters could occur through direct posttranslational modifi-
cation of PLZF and/or modification of transcriptional cofactors.
To investigate the former possibility, we immunoprecipitated
PLZF from control and IFNa-treated U937T:PLZF45 cells and
probed the acetylation or phosphorylation state of the protein
by immunoblotting. Although acetylation has been reported to
be important for DNA binding of PLZF (Guidez et al., 2005), no
change in the acetylation state was detected (data not shown).
However, PLZF was found to be phosphorylated at serine and
tyrosine residues, with tyrosine phosphorylation correlating
with temporal treatment with IFNa (Figure 6A). PLZF encodes
two types of conserved domain, a BTB domain at the N terminus
and nine repeated zinc finger domains at the C terminus.
Because BTB domains have been shown to be crucial for homo-
dimerization and protein-protein interaction (Dong et al., 1996),
we chose to focus on residues within this domain. Through align-
ment of the amino acid sequence of PLZF with BTB domains
from various other proteins and by analysis with prediction
programs (NetPhos 2.0, Department of Systems Biology, Tech-
nical University of Denmark), several putative phosphorylated
residues within the BTB domain of PLZF were identified along
with residues previously shown to be crucial for PLZF to function
as a transcriptional repressor (Figures S8–S10). We mutated
residues in PLZF to test their significance in the IFNa-mediated
induction of the Rsad2 promoter. This approach identified the
tyrosine at position 88 and a serine residue at amino acid 76 to(F) PLZF expression correlates with IFIT2 induction in response to IFNa in WT and Zbtb16/mice. PLZF expression was determined in multiple organs including
thymus. Mice were then injected with PBS or IFNa (1 3 105 IU), and after 8 hr, multiple organs were removed and RNA was extracted. IFIT1 and IFIT2 mRNA
expression was analyzed by real-time RT-PCR, with a custom ISG probe (top panels). Data are representative of three independent experiments (mean ± SEM).Immunity 30, 802–816, June 19, 2009 ª2009 Elsevier Inc. 807
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Figure 4. NK Cell Activation Is Impaired in Zbtb16/ Mice
(A) Expression of the gene encoding PLZF in mouse spleen lymphocytes. Quantitative RT-PCR analysis of PLZF transcripts, relative to the expression of 18S
mRNA, in various sorted lymphocyte populations. Results are the means of three independent experiments (mean ± SD).
(B) NK cell numbers in the spleens of Zbtb16/ and wild-type (WT) mice. NK cell populations (NK1.1+CD49b+) were assessed by flow cytometry. Data (mean ±
SD) are representative of three experiments.
(C) Diminished NK cell activity in Zbtb16/mice. Splenocytes labeled with carboxy-fluorescein diacetate succinimidyl ester (CFSE) were incubated for 4 hr with
NK-sensitive YAC-target cells at the indicated effector-to-target (E:T) ratios. Lysed cells were detected by 7-amino-actinomycin D (7-AAD) incorporation. Mice
were injected intraperitoneally with 10 mg of poly(I:C) 24 h (top panel), or IFNa1 2 days (bottom panel) before splenocyte isolation. Data are representative of four
independent experiments (mean ± SD).
(D) WT and Zbtb16/mice were injected i.p. with 50 mg poly(I:C) or PBS (control), and after 24 hr, splenic NK1.1+ CD3 NK cell expression of intracellular Gzmb
was analyzed by flow cytometry. Flow cytometry data representative of at least five independent experiments are shown in the WT, with a significant increase in
the percentage of NK cells positive (mean ± SD) for Gzmb after poly(I:C) injection.be important for induction of Rsad2 (Figure 6C). Consistent with
these promoter reporter assays, phosphorylation analysis of the
full-length mutant protein (S76A) indicated that the residue at
position 76 was the sole phosphoserine residue of importance
in IFN-mediated activation (Figure 6B). Two additional muta-
tions, R49D and L103E, which had previously been demon-
strated to constitute important structural components on either
surface of the BTB domain, had opposing effects upon ISG
induction. As anticipated, the L103E mutation impaired activa-
tion of Rsad2. Surprisingly, mutation of R49 induced the Rsad2
reporter. Although the structure of the charged pocket that
surrounds the R49 residue had been demonstrated to be critical
for PLZF to function as a transcriptional repressor, these results
suggest that other residues of the BTB domain on the lateral808 Immunity 30, 802–816, June 19, 2009 ª2009 Elsevier Inc.surface, where L103 lies, may be more pertinent to the role of
PLZF as a transcription inducer.
To identify the kinase that phosphorylates PLZF, we con-
ducted reporter assays (using Rsad2-luciferase) in cells treated
with kinase inhibitors or cell lines defective in components of
the IFN signaling pathway. Predictably, mutations in the JAK-
STAT pathway led to the impairment of all IFN signaling for
PLZF-regulated ISGs (Figure S11). Treatment of HeLa cells with
pharmacological inhibitors of ERK (PD98059), JNK (SP600125),
p38 (SB203580), Src (AZD0530), PI3K (AS-252424), or JAK2
(JAK2 inhibitor II), followed by stimulation with IFN, points to
JNK as a possible PLZF kinase (Figures 6D and 6E), or at least
a critical kinase in the pathway, and supports the importance of
serine phosphorylation of the protein (Figure 6B).
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Figure 5. PLZF Directly Regulates the Promoters of a Subset of ISGs
(A–C) Overexpression of PLZF in RCC1 and ACHN cells induces RSAD2 and IFIT2 promoter activity. RCC1 or ACHN cells were cotransfectedwith a PLZF expres-
sion plasmid and RSAD2-Luc or IFIT2-Luc promoter reporter constructs, then treated with IFNa1 (500 IU/ml of IFNa1). The luciferase values were obtained in at
least three independent experiments.
(D) Immunoblot analysis of PLZF in RCC1 cells expressing targeted or control miRNA (top panel). Luciferase assay for RSAD2 promoter induction in RCC1 cells
expressing miRNAs targeting PLZF (PLZF1.3 and PLZF2.4) or the control miRNA targeting LacZ (LacZ) then stimulated with IFNa (bottom panel) is shown.
Data are representative of three independent experiments (mean ± SD; A–D).
(E) Chromatin from PLZF-inducible (FLAG-tagged) U937T cells grown in the presence or absence of tetracycline (24 hr) and IFNa (1,000 U/ml for 6 or 24 hr)
was immunoprecipitated with a FLAG antibody. Promoters of PLZF-dependent RSAD2, IFIT2, and PLZF-independent IFI15 were amplified from the immu-
noprecipitated PLZF-FLAG chromatin with SYBR Green quantitative RT-PCR. Data represent the relative amount of genomic DNA from each promoter
normalized to 10% input DNA at each point.PLZF Regulates ISGs through Interaction
with HDAC1 and PML
IFN-enhanced association of PLZF with select ISG promoters
could also occur through regulation of transcriptional cofactors.
Accordingly, we sought to measure IFN-induced changes in
known PLZF cofactors. Transcriptional repression by PLZF is
sensitive to inhibitors of deacetylation, and PLZF physically inter-
acts with both class I and II histone deacetylases (HDACs) via the
BTB domain (Ahmad et al., 1998; Chauchereau et al., 2004;
David et al., 1998). In accord with a requirement for HDAC
activity for transcriptional activation of ISGs by PLZF, treatment
of cells with the HDAC inhibitor trichostatin A (TSA) blocked
induction of selected ISGs in the PLZF-inducible U937T:PLZF45
cells or BMMs (Figures 7A and 7B). An association between the
class I histone deacetylase HDAC1 and PLZF was shown by
coimmunoprecipitation of overexpressed FLAG-tagged PLZF
in HEK293 cells. Notably, an association with the class II histone
deacetylase HDAC4 was not detected under the same condi-tions (Figure 7C). This association between PLZF and HDAC1
was confirmed with endogenous protein under more physiolog-
ically relevant conditions in primary BMMs (Figure 7D). As
an additional measure of co-operation between PLZF and
HDAC1, the effect of coexpressing PLZF and HDAC1 upon the
Rsad2 reporter was measured in IFN-responsive RCC1 cells.
Appropriately, coexpression of PLZF with HDAC1 enhanced
the induction of the ISG promoter by IFNa to a greater degree
than that observed with either protein expressed alone. More-
over, treatment with TSA blocked the additive effect of PLZF
and HDAC1 (Figure 7E).
A second transcription factor reported to associate with PLZF
is the promyelocytic leukemia protein (PML) (Koken et al., 1997;
Regad and Chelbi-Alix, 2001). Of relevance to this study, PML
mediates the formation of nuclear bodies that are crucial in the
IFN response.More directly, it has been established that the anti-
viral response is reduced in PML-deficient MEFs (Day et al.,
2004). To determinewhether PML is a cofactor inPLZF-mediatedImmunity 30, 802–816, June 19, 2009 ª2009 Elsevier Inc. 809
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Figure 6. IFN Activates PLZF
(A) Phosphorylation of wild-type PLZF after IFNa stimulation. PLZF-inducible U937T cells grown in the presence or absence of tetracycline for 24 hr and IFN for
the times indicated were immunoprecipitated (IP) with a PLZF antibody and immunoblotted (IB) with phospho-Tyr Ab (top panel) or phospho-Ser Ab (bottom
panel).
(B) Serine76 is required for PLZF phosphorylation in response to IFNa. HeLa cells were transiently transfected with wild-type (WT) FLAG-PLZF or various mutant
PLZF expression plasmids; this was followed by IFNa treatment, immunoprecipitation (IP) with the FLAG antibody, and immunoblotting (IB) with a phosphoserine
or FLAG antibody, as indicated. The bar graph shows the proportion of phosphoserine residues on WT and mutant PLZF, treated with or without IFNa.
(C) Luciferase assay for RSAD2 promoter induction in lysates of RCC1 cells transfected with wild-type (WT) or indicated mutant PLZF expression plasmids, fol-
lowed by stimulation with IFNa. The values obtained from at least three independent transfection experiments were normalized to TK Renilla.
(D) HeLa cells were transfected with PLZF expression and RSAD2 promoter reporter plasmids. The cells were then either left untreated or were treated with inhib-
itors of ERK (5 mMPD98059), JNK (1 mMSP600125), p38 (2.5 mMSB203580), Src (1 mMAZD0530), PI3K (1 mMAS-252424), or JAK2 (0.5 mMJAK2 inhibitor II); they
subsequently underwent IFNa stimulation for 8 hr before RSAD2 promoter reporter activity in cell lysates was measured.
(E) Luciferase assay for RSAD2 promoter induction in lysates of HeLa cells overexpressing PLZF and pretreated with different concentrations of JNK inhibitor,
followed by IFNa stimulation. Data are representative of three independent experiments (mean ± SD; C–E).activation of ISGs, we performed coimmunoprecipitation assays
on lysates from the IFN-responsive HeLa cells, overexpressing
PLZF-tagged constructs, or on endogenous PLZF from primary
BMMs. PLZF was found to interact with PML in both cell types
after IFNa treatment (Figures 7F, 7G; Figures S12 and S13).
Importantly, PML has been demonstrated to alter the cellular
location of PLZF (Koken et al., 1997). To show whether the asso-
ciation between PLZF and PML, detected by immunoprecipita-
tion, correlated with colocalization of the proteins within nuclear
bodies, we performed confocal microscopy with fluorescently810 Immunity 30, 802–816, June 19, 2009 ª2009 Elsevier Inc.tagged proteins in RCC1 cells treated with or without IFNa. Indi-
rect immunofluoresence confirmed that PLZF localizedwith PML
after IFN stimulation (Figure 7H). The reported induction of PML
by IFN does not account for the observed colocalization, given
that the amounts of PML did not significantly increase over the
duration of this experiment (Figure S14). Together, these data
show that IFN treatment induces phosphorylation of PLZF, plau-
sibly by JNK, and interaction with both HDAC1 and PML to
mediate association of the complex with PLZF-binding sites in
gene promoters to induce specific ISGs.
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Figure 7. PLZF Regulates ISGs through Interaction with HDAC1 and PML
(A) Relative transcript levels of RSAD2, IFIT2, and IFI15, after tetracycline withdrawal for the PLZF-inducible U937T cells, treated with TSA prior to huIFN-a2b.
RNA was extracted and ISG expression was measured by real time RT-PCR. Data are shown as RSAD2, IFIT2 and IFI15 RNA levels normalized to GAPDH RNA.
(B) Transcript levels of RSAD2 and IFIT2measured by real-time RT-PCR in wild-type (WT) and Zbtb16/BMMs. Cells were treated with IFNa, TSA alone, or IFNa
and TSA. Data are shown as RNA expression levels normalized to 18S RNA and are representative of three independent experiments (mean ± SEM; A and B).
(C) Cell lysates prepared from HEK293T cells transiently transfected with FLAG-PLZF, immunoprecipitated (IP) with the FLAG antibody, and immunoblotted (IB)
with anti-HDAC1 or anti-HDAC4.
(D) WT and Zbtb16/ BMMs were incubated in the absence or presence of IFNa. Cell lysates were immunoprecipitated with PLZF antibody and immunoblotted
with HDAC1 antibody.
(E) RCC1 cells expressing PLZF and HDAC1 alone or in combination were stimulated with IFNa, TSA alone, or IFNa and TSA. Relative RSAD2 promoter activity
was determined by activity of RSAD2 luciferase assay and normalization to TK Renilla. Data are representative of three independent experiments (mean ± SD).
(F) HeLa cells were transiently transfected with FLAG-PLZF; this was followed by IFNa treatment, immunoprecipitation with the FLAG antibody, and immuno-
blotting with a PML or PLZF antibody, as indicated.
(G) WT and Zbtb16/ BMMs were incubated in the absence or presence of IFNa, immunoprecipitated with PLZF antibody, and immunoblotted with PML anti-
body.
(H) Confocal images of RCC1 cells transiently expressing PLZF-CFP with and without IFNa treatment. Arrows indicate the colocalization of PLZF with PML.
Images are representative of four independent experiments.Immunity 30, 802–816, June 19, 2009 ª2009 Elsevier Inc. 811DISCUSSION
Recent studies have shown that type I IFN signaling is more
complex than initially recognized, activating different specific
signals and patterns of gene expression (van Boxel-Dezaire
et al., 2006). The response via the canonical JAK-STAT pathway
alone is not sufficient to explain all the biological effects of type I
IFN. Accordingly, other kinases, including PI3K andMAP kinase,
lead to the activation of additional transcription factors such as
NF-kB, AP-1, IRFs, and PU.1, which interact with STATs at inter-
feron-stimulated response elements (ISREs) via ISGF3 or other
IRFs to regulate ISGs. We showed that the transcription factor
PLZF is a regulator of the IFN response. PLZF induced a specific
subset of ISGs with PLZF-binding sites in proximity to ISRE.
Gene array, chromatin immunoprecipitation (ChIP) assays, and
promoter reporter experiments demonstrated that PLZF directly
occupied these select promoter sequences and that this activitywas IFN dependent. In this study, analysis of all genes induced
by PLZF showed a predominance of ISGs, explicitly implicating
PLZF in positively modulating the IFN pathway.
Although PLZF has been designated as a transcriptional
repressor, our observation that PLZF promotes ISG transcription
is not without precedence (Labbaye et al., 2002; Senbonmatsu
et al., 2003). The mechanism for transcriptional repression by
PLZF is thought to involve constraint of the accessibility of the
gene to transcriptional machinery, via chromatin remodeling by
acetylation involving the nuclear corepressor complex (NCoR)
and HDACs, particularly HDACs 1 and 4 (Chauchereau et al.,
2004; David et al., 1998; Guidez et al., 2005; Hong et al., 1997;
McLoughlin et al., 2002). Although HDACs are generally consid-
ered as corepressors, HDAC1 could serve as a coactivator for
the glucocorticoid receptor (Qiu et al., 2006). More relevant to
our findings, we and others found that inhibition of HDAC1 per-
turbed IFN-induced transcription and antiviral responses.
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this protein is required for the efficient activation of ISGs (Chang
et al., 2004; Zupkovitz et al., 2006). Also, HDAC1 but not HDAC4
associated with STAT1 and STAT2 to positively activate expres-
sion of the ISG3-dependent transcriptional response. Corre-
spondingly, we detect an association between PLZF and
HDAC1, not HDAC4, upon stimulation with IFNa, leading us to
propose that HDAC1 is key to PLZF’s role as a transcriptional
enhancer. Similarly to HDAC1, a second PLZF cofactor, PML,
is indispensable for the IFN response (Handwerger and Gall,
2006). Appropriately, PML is induced by IFN through an ISRE
and an IFN-g activation site (GAS) motif in its promoter, and
the number and intensity of nuclear bodies increase in response
to IFN (Stadler et al., 1995). More directly, it has been established
that the antiviral response is reduced in PML-deficient MEFs
(Day et al., 2004). We demonstrate here that PLZF and PML
associate and that this interaction is also modulated by IFN.
Although the precise mechanism modulating the association
between PLZF and its cofactors has not been established, it is
predicted to be mediated by the BTB domain of PLZF (Melnick
et al., 2000b). This domain acts as a homodimerization motif
that is essential for the repressor function of PLZF and its local-
ization in nuclear bodies. (Melnick et al., 2000a) Our results
suggest that this domain is also key for its transcriptional
enhancer function. However, our observations indicated differ-
ences in how the BTB domain mediates repressor or enhancer
activities of PLZF. Mutation of the residue at position 49 in the
BTB domain of PLZF, shown to be essential for repressor
activity, had the contradictory effect of further enhancing ISG
expression. Mutation of another key structural residue, on the
lateral face of the BTB domain at position 108, recapitulated
the loss of function as a repressor. This implies that different
regions of PLZF mediate repressor or enhancer functions.
Because we found an interaction between PLZF, PML, and
HDAC1 only after IFN stimulation, it seems likely that IFN
signaling affects the state of one or all of these proteins. Informa-
tively, the apparent paradoxical function of HDAC1 as a core-
pressor or coactivator appears to be regulated by acetylation
of the protein itself (Melnick et al., 2000a). It is also reported
that PLZF is both acetylated and phosphorylated (Ball et al.,
1999; Guidez et al., 2005). In this study, PLZF was found to be
phosphorylated at serine and tyrosine residues in response to
IFN, and we identified a serine residue (Ser76) that resides in
the BTB domain of PLZF and that was important for PLZF-medi-
ated ISG induction, thereby implicating a serine kinase in PLZF
activation. Accordingly, kinase inhibitor studies implicate the
serine kinase JNK as a potential activator of PLZF.
Recognition of PLZF-binding sites in proximity to ISRE
suggests cooperation between canonical IFN transcription
factors and PLZF. Only promoters containing both regulatory
elements show both PLZF- and IFN-dependent expression.
Experiments in STAT1-deficient cells demonstrate that this
factor is required for PLZF-dependent transcriptional induction,
as expected in IFN signaling. A direct comparison of PLZF-inde-
pendent and -dependent genes demonstrated that tissue-
specific expression patterns of the closely related ISGs IFIT1
and IFIT2 may be determined by PLZF. We demonstrated that
PLZF associates with other essential cofactors, PML and
HDAC1. Consequently, we propose a model whereby PLZF812 Immunity 30, 802–816, June 19, 2009 ª2009 Elsevier Inc.functions to stabilize a transcription complex that minimally
includes STATs, HDAC1, and PML to mediate the expression
of specific ISGs.
Although only a subset of ISGs is regulated by PLZF, the
observed impairment is physiologically critical because it is
sufficient to severely compromise the antiviral immune
response. We showed this immune impairment was due to
direct defects in key IFN-mediated antiviral factors and to indi-
rect mechanisms that modulate NK cell activity. The reduced
viral load in the presence of PLZF and IFN suggests that IFN-
improved survival after SFV infection requires PLZF. This corre-
lates with regulation of the expression of the antiviral mediator
OAS1. OAS1 combined with the ribonuclease L (RNaseL) consti-
tutes an antiviral RNA decay pathway previously demonstrated
to regulate SFV infection (Silverman, 2007). Impaired induction
of other ISGs such as IFIT2 and RSAD2, which have recently
been shown to function as antiviral effectors, was also found
(Borden et al., 2007). Other ISGs identified as having impaired
induction in Zbtb16/ cells, most pertinently CXCL10, do not
have a direct antiviral function. CXCL10 has been demonstrated,
with other chemokines, to regulate NK cell function (Biron et al.,
1999). A recent study comparing wild-type and Cxcl10/ mice
has shown that CXCL10 expression promotes protection from
coronavirus-induced neurological and liver disease (Walsh
et al., 2007). Furthermore, a study using Cxcl9/ and
Cxcl10/ mice has found that these chemokines are critical
for the control of Herpes Simplex Virus infection through mobi-
lization of NK cells and CTL to sites of infection (Thapa et al.,
2008). IFN has an established role in the function of NK cells
and influences NK activation during viral infection. Defects in
NK cell activity, such as decreased production of IFN, also
render mice more susceptible to viral infection (Lee et al.,
2007). However, impaired NK cell function in Zbtb16/ mice
is independent of IFN production. Instead, we propose that
the observed defect in NK cell activity in the Zbtb16/ mouse
is due to impairment of specific ISGs, with CXCL10 identified
as a likely candidate. Zbtb16/ mice show a marked decrease
in CXCL10 expression in NK cell-rich organs, and such
a decrease may lead to impaired mobility of NK cells, and there-
fore ineffective viral clearance. IFN-induced activation of NK
cells resulted in potent cytotoxicity associated with a dramatic
increase in GzmB. GzmB expression is essential for eliciting
NK cell cytotoxic function and is responsible for the rapid induc-
tion of caspase-dependent apoptosis. Previous studies have
demonstrated GzmB is an ISG (Cao et al., 2007; Zimmerer
et al., 2007). However, the regulation of GzmB expression is
not understood. Intriguingly, the GzmB promoter contains
a binding site for PLZF, raising the possibility that PLZF directly
regulates GzmB transcription. The findings here suggest that
IFN-mediated activation of NK cells is regulated by PLZF.
Until recently, PLZF had not been ascribed any role in immune
regulation. However, two recent reports demonstrate that PLZF
is also expressed in NK T cells and that the transcription factor is
essential to the development of these cells (Kovalovsky et al.,
2008; Savage et al., 2008). Here, we showed that PLZF is also
expressed in NK cells and provide evidence that PLZF is pivotal
in the IFN-dependent activation of NK cells. The finding
described here provides evidence that PLZF plays an important
role in innate immunity via modulation of the IFN response. PLZF
Immunity
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Immunity 30, 802–816, June 19, 2009 ª2009 Elsevier Inc. 813regulates a key subset of ISGs with consequences for the arche-
typal function of IFN, to instigate resistance to virus infection.
EXPERIMENTAL PROCEDURES
Cell Lines and Treatments
RCC1 (Campbell et al., 1998) and ACHN (ATCC CRL-1611) cells were main-
tained in RPMI and DMEM, respectively. The U937T:PLZF45 inducible PLZF
system was previously described (McConnell et al., 2003) and is based on
the U937T autoregulatory tet-off system, in which withdrawal of tetracycline
leads to gene expression. Actinomycin D was added to cells at a final concen-
tration of 5 mg/ml for 8 hr prior to IFN treatment. Trichostatin A was added to
cells at a final concentration of 25 ng/ml for 8–24 hr prior to IFN treatment.
We obtained spleen macrophages and BMMs from age-matched WT and
Zbtb16/ mice as previously described (Barna et al., 2000). BMMs were iso-
lated from mice and cultured as described (Sweet et al., 2001). Cells were
plated at a density of 1 3 107 cells/plate and were cultured for an additional
24 hr without colony-stimulating factor 1. Cells were treated with 500–1000
IU/ml of IFNa1, then collected at 3, 6, and 9 hr for gene expression analysis.
Microarray
Previously obtained data of Affymetrix HG_U95Av2 expression profiles 24 and
48 hr after PLZF expression, performed in biological triplicate, were analyzed
for genes with significant changes in gene expression as a result of PLZF
expression with Significance Analysis of Microarrays (SAM; http://www-stat.
stanford.edu/tibs/SAM/) (McConnell et al., 2003; Tusher et al., 2001). RNA
was extracted from control and IFN-treated U937T PLZF cells with Trizol
reagent (Invitrogen). Labeling and hybridization to the custom ISG cDNA array
were performed as described previously (Frevel et al., 2003; Sledz and Wil-
liams, 2004). Analysis was performed with GeneSpring 5.0 (Agilent). Data
were first normalized with LOWESS normalization for each experiment, and
then each array was normalized to the intensity of GAPDH expression so
that intensities across samples could be compared. Genes with unreliable
expression intensities below 300 for the induced sample (IFN-treated, PLZF-
expressing, or PLZF-expressing IFN-treated) were discarded from further
analyses. Data were filtered for genes induced over 2-fold in PLZF-expressing
cells, and genes whose expression was 2-fold higher with PLZF and IFN treat-
ment over IFN treatment alone were defined as PLZF responsive. PLZF-
responsive genes were partitioned into seven sets with K-means cluster anal-
ysis with a standard correlation and 100 iterations.
Quantitative Real-Time PCR
Total RNA was extracted from cells with Trizol reagent (Invitrogen), and cDNA
was produced with random hexamer primers and Superscript III reverse tran-
scriptase (Invitrogen). PCR was performed on an Applied Biosystems 7700
Prism real-time PCR machine with the manufacturer’s SYBR green kit and
instructions (Applied Biosystems). Expression analysis of human samples by
real-time PCR was done with the primers listed in the Supplemental Experi-
mental Procedures. The 2-LLCt method was used for analysis with the
untreated sample as the reference. Quantitative-PCR (Q-PCR) was performed
in mouse samples. Predeveloped TaqMan probe/primers for RASD2, IFIT1,
IFIT2, 20-50OAS, CXCL10, and CCL5 (Applied Biosystems) were used for
calculation of the threshold cycle numbers that were transformed with the
cycle threshold and relative value method as described by the manufacturer
and were expressed relative to 18S ribosomal RNA. Results are expressed
as relative gene expression for each target gene.
Bioinformatic Analysis
To elucidate functional similarities among the genes induced by PLZF, we
mined gene ontologies by using the Expression Analysis Systematic Explorer
(EASE) Functional Annotation Tool Suite. Promoters were retrieved with Pro-
moser and potential binding sites were identified with MatInspector (Genoma-
tix Suite). Overrepresented motifs were identified with MEME and JASPAR
(Bailey and Elkan, 1995; Stormo, 2000) with the ‘‘-zoop’’ option, which indi-
cates ‘‘zero or one occurrence per sequence,’’ and motif width was set
between 6 and 15 bp. Gene promoters that contain the ten most frequently
occurring motifs were selected for further analysis. For each of these, the posi-tional specific scoring matrix (PSSM) generated by MEME was searched
against the TRANSFAC database with the MALIGN algorithm (Haverty et al.,
2004). The PLZF BTB domain was analyzed with the Conserved Domain Data-
base and TCoffee. PLZF protein sequence was run by the NetPhos 2.0 server
program for predictions of serine, threonine, and tyrosine phosphorylation
sites. The above bioinformatic analyses used the web programs listed in
Supplemental Experimental Procedures.
Chromatin Immunoprecipitation Assay
Chromatin immunoprecipitation assays were done in accordance with the
manufacturer’s instructions (Upstate Biology). The presence of the target
gene promoter sequences in both the input DNA and the recovered DNA im-
munocomplexes was detected by quantitative PCR. The antibodies used for
ChIP were against PLZF (Calbiochem) and FLAG M2 (Sigma). After reversal
of the crosslinking, DNA was recovered by phenol-chloroform extraction
and ethanol precipitation and then used in a PCR. The sequences of the
primers used for the PCR are listed in the Supplemental Experimental Proce-
dures. PCR for IFIT2, RSAD2, and ISG15 was performed with a Sybr Green
PCR mastermix (AP Biotech) on an iCycler PCR machine (Biorad).
Immunoprecipitation and Immunoblotting Analysis
For immunoprecipitation, cells were lysed with triple detergent lysis buffer and
incubated with antibodies (anti-PLZF and anti-FLAG) as indicated. Antibody
complexes were isolated with protein A/G-agarose beads (Pharmacia
Biotech), and immunocomplexes were analyzed by SDS-PAGE and immuno-
blotting with anti-phospho Ser, anti-phosphoTyr (Upstate), anti-PLZF, anti-
PML, anti-HDAC1, or anti-HDAC4. Expression of PLZF was assessed by
immunoblotting with anti-PLZF (Calbiochem). Protein bands were detected
and quantified on a Li-Cor Odyssey infrared imaging system or exposure of
the membrane to BioMax autoradiographic film (Kodak).
RNAi-Mediated PLZF Knockdown
Knockdown of PLZF was induced by transfection of BLOCK-iT Pol II miR RNAi
Expression Vector (RNAi PLZF plasmids targeting two different sequences in
PLZF, and LacZ as control). The miRNA (plzf) target sequences were: miRNAi
plzf13 (437-456), 50-TGCTGTATAGTGTTGACTATTGCGGTTTTGGCCACTG
ACTGACCGCAATAGTCAACACTATA-30; and miRNAi plzf24 (1116-1135),
50-TGCTGTAGTGTAGCTCCCTAGCACGTTTTGGCCACTGACTGACGTGCTA
GGGAGCTACACTA-30. Starting 24 hr after transfection, untransfected cells
were eliminated by culturing the cells in the presence of 10 mg/ml blasticidin
for 10–14 days. Total cellular RNA was isolated and whole-cell lysates were
used for immunoblotting. The efficiency of the knockdown was assessed at
the protein level by immunoblotting.
Transfection Assay and Luciferase Assays
The RASD2 luciferase reporter was provided by K. Fitzgerald (Severa et al.,
2006), and the IFIT2 luciferase reporter was cloned by PCR. All plasmids
used in the transfection assay were prepared with the endotoxin-free plasmid
Maxi-kit (QIAGEN). A total 23 105 RCC1 or ACNH cells were incubated over-
night. The wild-type and mutant RSAD2 promoter reporter gene vector (1 mg),
along with 0.2 mg of a phRL-TK Synthetic Renilla expression vector, were
transfected into cells with Fugene 6 (Roche). After transfection for 24 hr, the
cells were harvested and lysed. Luciferase activity was generated with lucif-
erase substrate and read out in opaque 96-well plates with a plate-reading
luminometer. phRL-TK Synthetic Renilla was cotransfected for normalization
of transfection efficiency. Experiments were performed in triplicate.
Immunofluorescence
Approximately 1 to 2 3 105 cells were seeded in Chamber slides (Lab-Tek II,
Nalge Nunc International). The 60%–80% confluent culture of cells was
treated with IFNa for 2–4 hr. The cells were then fixed with 4% paraformalde-
hyde and blocked with CAS blocking solution (Zymed). The cells were incu-
bated with the PML (Santa Cruz) primary antibody, incubated sequentially
with FITC-conjugated anti-rabbit secondary antibodies (Molecular Probes),
and analyzed by fluorescence or confocal microscopy (Leica Instruments).
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Wild-type and Zbtb16/ primary MEFs were generated. Cells were seeded
into 96-well plates at 1 3 104 cells/well and incubated overnight, treated
with serial dilutions of mouse IFN-a1 for 16 hr, and challenged with SFV virus
(105–107 plaque-forming units [pfu]) for an additional 48 and 72 hr. Viral titers
were determined as the dilution at which 50% death occurred and are ex-
pressed as log10 titers or as ‘‘fold dilution’’ (Fenner et al., 2006). Cells were
fixed with cold methanol and stained with crystal violet, before optical density
at 620 nm was read.
Viral Infection of Mice
Pups between 5 and 6 days of age were injected intraperitoneally (i.p.) with
50 ml SFV at 103, 303, and 1003 TCID50, determined by CPE bioassay of
mouse L929 cell cultures. Some mice were preinjected with mouse IFNa
6 hr before viral infection. Themouse IFNa titer was verified in a CPE-reduction
bioassay. Experiments with wild-type and Zbtb16/ mice used littermate
controls and were conducted by researchers ‘‘blinded’’ to experimental condi-
tions, with genotypes being determined after completion of the experiments.
Mice were monitored at 36 hr intervals and resistance was recorded for up
to 3 weeks. Viral titers of each organ were measured at day 3 of SFV infection
and IFN pretreatment (Fenner et al., 2006). For in vivo infections with EMCV,
500 pfu were injected i.p. into Zbtb16/ mice and wild-type littermate
controls. These studies were approved by the Monash University Monash
Medical Centre A Animal Ethics Committee (Melbourne, Australia).
Serum Interferon Assays
Serum samples from neonatal mice were diluted in semi-log10 steps in dupli-
cate into 96-well plates containing L929 cell monolayers. The medium was
removed 16 hr later and SFV added at a concentration of 103 TCID50 in fresh
RPMI medium. Plates were subsequently incubated for 4872 hr, after which
they were assigned scores for CPE. This assay measures the activity of all type
I and type II interferons. The interferon activity (IU/ml) was calculated by
comparison of the titer of the sample with a laboratory IFNa standard cali-
brated to the National Institutes of Health reference standard Ga02-901-511.
Cytotoxicity Assay
This flow cytometric method, previously described by Lecoeur et al. (2001),
entails labeling effector cells with carboxy-fluorescein diacetate succinimidyl
ester (CFSE) so that they could be discriminated from target cells, then adding
7-amino-actinomycin D (7-AAD) so that killed targets could be labeled. Mice
were injected i.p. with 0.1 ml of PBS containing poly(I:C) (10 mg/mouse) or
IFNa (1 3 105 IU/mouse), and splenocytes were harvested after 24 or 60 hr,
respectively, and labeled with CFSE. In vitro NK lysis was monitored by incu-
bation of different numbers of CFSE-labeled effector cells with 1 3 104 target
cells (YAC-1 cells) at 37C for 4 hr. In parallel, target cells were incubated alone
for basal apoptosis measurement. Immediately before analysis, 1 mg/ml (final
concentration) of 7-AAD was added to each sample and incubated for 20 min.
The percentage of apoptotic (7-AADlo+7-AADhi) cells is used for calculating the
percentage of specific lysis according to the following formula:%specific lysis =
100 3 (% sample lysis – % basal lysis)/(100  % basal lysis). Sample lysis is
the cell lysis in the presence of effectors at a given E:T ratio, and basal lysis
is the cell lysis in the absence of effectors.
Cell Isolation and Stimulation
Spleens were harvested and single-cell suspensions were generated. Red
blood cells were lysed and the cells were washed in RPMI medium. For
in vitro cytokine stimulation, splenocytes were plated at 10 3 106/ml in
24-well plates in 1000 U/ml IL-2. Cells were harvested by pipetting with cold
PBS after 48 hr and analyzed by flow cytometry. For cell sorting, splenocytes
were surface stained with anti-NK1.1, anti-CD3, and anti-B220 (BD Biosci-
ences PharMingen), and CD3+NK1.1, CD3NK1.1+, or B220 cells were iso-
lated by cell sorter (routinelyR99% pure).
Intracellular Staining and Flow Cytometry
Splenocytes or tissue mononuclear cells were stained for surface markers
(NK1.1) and intracellular Gzmb as described (eBioscience Foxp3 staining
protocol) with directly conjugated Gzmb (1:400 dilution) monoclonal anti-814 Immunity 30, 802–816, June 19, 2009 ª2009 Elsevier Inc.bodies. Sample data were acquired on a Cytek-modified FACScan (BD) flow
cytometer, and isotype controls were used to set quadrant gates.
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